Domain mapping of disease mutations supports genetic testing of specific SORL1 variants in familial Alzheimer’s Disease

Abstract
Background Protein truncating variants (PTVs) in SORL1 are observed almost exclusively in Alzheimer’s Disease (AD) cases, but the effect of rare SORL1 missense variants is unclear.
Methods To identify high-priority missense variants (HPVs), we applied ‘domain mapping of disease mutations’ on the 637 unique coding SORL1 variants detected in 18,959 AD-cases and 21,893 non-demented controls.
Results In this sample, PTVs and HPVs associated with respectively a 35- and 10-fold increased risk of early onset AD and 17- and 6-fold increased risk of overall AD. The median age at onset (AAO) of PTV- and HPV-carriers was 62 and 64 years, and APOE-genotype contributed to AAO-variability. The median AAO of PTV- and HPV-carriers is ∼8-10 years earlier than wild-type SORL1 carriers, matched for APOE-genotype. Specific HPVs are highly penetrant and lead to earlier AAOs than PTVs, suggesting possible dominant negative effects.
Conclusion Our results justify a debate on whether HPV carriers should be considered for clinical counseling.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by EU Joint Programme-Neurodegenerative Disease Research (JPND) Working Group. holstegelab was supported by: https://holstegelab.eu/supported-by/
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Amsterdam UMC VUmc gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The general body of the text has been improved and made more concise, with updates in the Methods, Results, and Discussion sections.
Data Availability
All data produced in the present work are contained in the manuscript.
Subject Area
- Addiction Medicine (410)
- Allergy and Immunology (725)
- Anesthesia (214)
- Cardiovascular Medicine (3086)
- Dermatology (260)
- Emergency Medicine (462)
- Epidemiology (13014)
- Forensic Medicine (13)
- Gastroenterology (860)
- Genetic and Genomic Medicine (4834)
- Geriatric Medicine (445)
- Health Economics (750)
- Health Informatics (3056)
- Health Policy (1101)
- Hematology (408)
- HIV/AIDS (956)
- Medical Education (453)
- Medical Ethics (119)
- Nephrology (499)
- Neurology (4605)
- Nursing (244)
- Nutrition (684)
- Oncology (2385)
- Ophthalmology (673)
- Orthopedics (268)
- Otolaryngology (333)
- Pain Medicine (300)
- Palliative Medicine (87)
- Pathology (514)
- Pediatrics (1239)
- Primary Care Research (520)
- Public and Global Health (7188)
- Radiology and Imaging (1601)
- Respiratory Medicine (943)
- Rheumatology (459)
- Sports Medicine (403)
- Surgery (509)
- Toxicology (65)
- Transplantation (221)
- Urology (189)